Results 231 to 240 of about 28,100,614 (312)

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemia. [PDF]

Br J Haematol
Moore CG, Chyong DI, Daver N, Aubrey BJ, Marx KR, Takahashi K, Abaza Y, Smith CC, Amrein PC, Hock H, Hobbs G, Narayan R, Lee MH, Moran JA, Bergeron M, Foster JE, Perl AE, Levis MJ, DiNardo CD, Brunner AM, Fathi AT.   +20 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Computational modeling-directed combination treatment with etanercept and mifepristone mitigates neuroinflammation in a mouse model of Gulf War Illness. [PDF]

PLoS One
Kelly KA, Felton CM, Billig BK, Yilmaz AA, O'Callaghan JP, Craddock TJA, Broderick G, Klimas N, Michalovicz LT.   +8 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. [PDF]

J Clin Sleep Med
Buysse DJ, Arnedt JT, Buenaver L, Chang JL, Fernandez-Mendoza J, Patel SI, Zhou ES, Falck-Ytter Y, Hyer S, Kazmi U, Singh M, Wickwire EM.   +11 more
europepmc   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment. [PDF]

J Immunother Precis Oncol
Watson A, D'Amato G, Jonczak E, Bialick S, Trent J.   +4 more
europepmc   +1 more source

Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk

Molecular Oncology, EarlyView.
Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley   +1 more source

CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy. [PDF]

J Bone Oncol
Su X, Kobayashi T, Xiang J, Xu Y, Shajahan-Haq AN, Mardani M, Noordeen S, O'Donnell K, Kwakwa KA, Guan D, Fox GC, Fontana F, Cybulla E, Bakewell S, Vindigni A, Veis DJ, Achilefu S, Lanza GM, Weilbaecher KN.   +18 more
europepmc   +1 more source